Cell and gene therapy 2.0 dominates latest round of biotech IPOs in scramble for a $300M-plus Nasdaq windfall
Back at the start of January last year, Poseida Therapeutics thought it had an IPO-worthy game plan that would sell on Wall Street. Instead, with the market in something of a dyspeptic mood, the San Diego-based startup with its next-gen approach to cell and gene therapy switched to a Series C mega round and dropped the IPO.
Until now, while the market is running red hot for all things drug-development related. And on Friday Nasdaq loaded up a new round of biotech IPOs to sell to investors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.